Jeremy Blimbaum advises EnobraQ
April 12, 2018
Created in 2015, EnobraQ, a company specialized in biotechnology, develops cutting-edge technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics.
Thanks to its innovative projects and discoveries made over the past two years, the Toulouse-based company has attracted the interest of the three big names in research, INRA, INSA and CNRS, and has thus been able to open its capital to them.
This opening is the second fundraising in 2 years for a cumulative amount of €4.9 million. Sofinnova Partners, Auriga Partners, Irdinov and SuperNovaInvest reaffirm their confidence. This financial support will make it possible to pursue development in three areas, and in particular to improve certain industrial production by up to 20%.
Jeremy Blimbaum, Partner in charge of the corporate finance and securities law practices, and Claire Coquard advise EnobraQ throughout this project.